Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation - Efficacy and Safety Results After the First Year of Treatment in the Real Life Setting.

Trial Profile

Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation - Efficacy and Safety Results After the First Year of Treatment in the Real Life Setting.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Ivacaftor (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Acronyms IVACAFTOR1
  • Most Recent Events

    • 31 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 15 Dec 2015 Planned number of patients changed from 58 to 57 as per ClinicalTrials.gov record.
    • 15 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Nov 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top